We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Qiagen and CytoPathfinder Combines Technologies in RNAi Screening

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Qiagen and CytoPathfinder Combines Technologies in RNAi Screening"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

Qiagen and CytoPathfinder have announced the formation of a strategic partnership between the two companies to combine their technologies in developing advanced tools for high-throughput RNAi screening.

CytoPathfinder has developed a Transfection Microarray technology (TMA) which allows high-throughput siRNA screening on a microarray chip. 

Both companies have agreed to combine product knowledge and technology platforms to develop new-generation tools for high-throughput RNAi screening. 

These developments have made high-throughput RNAi accessible to both pharmaceutical companies and academic researchers.